XDH and metabolic dysfunction-associated steatohepatitis: In a nonalcoholic steatohepatitis (NASH) mouse model, febuxostat significantly lowered hepatic XO activity and UA levels, leading to improvements in IR, lipid peroxidation, and the accumulation of classically activated M1-like macrophages in the liver (116).